Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 10;11:9896. doi: 10.1038/s41598-021-89134-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Kaplan–Meier and Aalen-Johansen survival by podocalyxin immunoexpression. (a) The association of disease-specific survival (DSS) and podocalyxin immunoexpression based on polyclonal (pAb), HPA2110 and monoclonal antibodies (mAb), HES9 combined among non-responders. A categorization for podocalyxin expression with three groups was created as follows: 1, strong staining for both pAb and mAb (both scored 3); 2, either exhibiting strong staining (either scored 3); and 3, both staining weakly (both scored 0–2), corresponding to strong, moderate, and weak, respectively. Non-responders were defined as a class 4 or 5 response corresponding to > 50% residual tumor cells. Kaplan–Meier analysis. Log-rank test was used for statistical significance. (b) The association of progression-free survival (PFS) and podocalyxin immunoexpression based on polyclonal (pAb) and monoclonal antibodies (mAb) combined among non-responders. A categorization for podocalyxin expression with three groups was created as follows: 1, strong staining for both pAb and mAb (both scored 3); 2, either exhibiting strong staining (either scored 3); and 3, both staining weakly (both scored 0–2), corresponding to strong, moderate, and weak, respectively. Non-responders were defined as a class 4 or 5 response corresponding to > 50% residual tumor cells. Death from any cause (overall survival, OS) was used as a competing event. Aalen-Johansen analysis. Gray's test was used for statistical significance. (c) The association of progression-free survival (PFS) and podocalyxin immunoexpression with polyclonal antibody HPA2110, (pAb) in the upfront surgery group. Podocalyxin expressions were grouped as follows: 1, strong staining for pAb (scored 3); and 2, moderate, weak or negative staining for pAb (scored 0–2) corresponding to strong and weak, respectively. Upfront surgery patients included for the analysis. Aalen-Johansen analysis. Death from any cause (overall survival, OS) was used as a competing event. Grays' test was used for statistical significance. (d) The association of progression-free survival (PFS) and podocalyxin immunoexpression with monoclonal antibody HES9, (mAb) in the upfront surgery group. Podocalyxin expressions were grouped as follows: 1, strong staining for mAb (scored 3); and 2, moderate, weak or negative staining for mAb (scored 0–2) corresponding to strong and weak, respectively. Upfront surgery patients included for the analysis. Aalen-Johansen analysis. Death from any cause (overall survival, OS) was used as a competing event. Grays' test was used for statistical significance.